An approach engineered in the Irvine and Wittrup labs to anchor powerful immune medicines at the tumor site—thus avoiding challenges of both systemic and intratumoral delivery—is headed to trials. Ankyra Therapeutics, which the researchers co-founded, announced approval of its investigational new drug application by the US FDA and clinical trial application by Health Canada for its lead agent, ANK-101.
Watch or read more to learn about the original research, supported in part by the Marble Center for Cancer Nanomedicine, the Hope Babette Tang (1983) Student Research Fund, the Kristin R. Pressman and Jessica J. Pourian (2013) Koch Institute Fund, the Charles S. Krakauer (1954) Fund, and a KI Quinquennial Cancer Research Fellowship.